Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thyroidal response to an increase or decrease of endogenous TSH in patients with hyperthyroidism and its correlation

M Katakura, Y Koizumi, T Aizawa

    Clinical and Experimental Pharmacology & Physiology
    |May 1, 1986
    PubMed
    Summary

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.

    British journal of cancer·2014
    Same author

    Randomized clinical trial: rikkunshito in the treatment of functional dyspepsia--a multicenter, double-blind, randomized, placebo-controlled study.

    Neurogastroenterology and motility·2014
    Same author

    Combination of platelet count and neutrophil to lymphocyte ratio is a useful predictor of postoperative survival in patients with colorectal cancer.

    British journal of cancer·2013
    Same author

    The prognostic significance of vasohibin-1 expression in patients with prostate cancer.

    British journal of cancer·2013
    Same author

    Clinical impact of circulating miR-18a in plasma of patients with oesophageal squamous cell carcinoma.

    British journal of cancer·2013
    Same author

    Overexpression of YWHAZ relates to tumor cell proliferation and malignant outcome of gastric carcinoma.

    British journal of cancer·2013

    Antithyroid drugs reduce TSH binding inhibiting immunoglobulin (TBII) in Graves' disease. Long-term therapy showed thyroidal responsiveness to TSH changes did not correlate with TBII presence.

    Area of Science:

    • Endocrinology
    • Immunology

    Background:

    • Graves' disease is an autoimmune disorder causing hyperthyroidism.
    • Thyroid-stimulating immunoglobulin (TSI) and TSH binding inhibiting immunoglobulin (TBII) are key autoantibodies.
    • Antithyroid drugs are a primary treatment for Graves' disease.

    Purpose of the Study:

    • To investigate the relationship between TBII activity and thyroidal responsiveness to TSH fluctuations during long-term antithyroid drug therapy in Graves' disease patients.
    • To assess changes in TSI activity over the treatment period.

    Main Methods:

    • 121 Graves' disease patients received antithyroid drugs for 3 years.
    • Evaluated thyroidal response to TSH changes (T3 suppression tests).
    • Measured serum TBII and TSI activity, and TSH/T4/T3 levels post-TRH stimulation.

    Related Experiment Videos

    Main Results:

    • TBII activity decreased over time during therapy, present in 83% of untreated patients.
    • T3 suppression of radioactive iodine uptake was less effective in patients with TBII activity.
    • TSI activity became undetectable after 3 years; TSH/T4/T3 responses to TRH were normal in all patients.

    Conclusions:

    • Long-term antithyroid drug treatment impacts TBII levels in Graves' disease.
    • In vivo thyroidal responsiveness to TSH variations did not correlate with TBII presence after prolonged therapy.
    • TSI levels normalize with treatment, suggesting a potential disconnect from TBII activity's impact on TSH response.